Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 3:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 20,596 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune Dysfunction Clear all
Completed Not applicable Interventional

Test of an Intervention to Improve HIV Care

NCT01103856
View directory record Official record
Conditions
HIV Infection
Interventions
Patient Mentor Intervention, HIV transmission risk reduction
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Oct 18, 2026, 3:55 AM EDT
Recruiting Not applicable Interventional

Improving Hypertension Control in Rheumatoid Arthritis

NCT05760898
View directory record Official record
Conditions
Hypertension, Rheumatoid Arthritis
Interventions
Blood pressure intervention arm
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 18, 2026, 3:55 AM EDT
Completed Phase 2 Interventional Results available

Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT01256398
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Interventions
Alemtuzumab, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Etoposide Phosphate, Filgrastim, Fludarabine Phosphate, In Vitro-Treated Peripheral Blood Stem Cell Transplantation, Laboratory Biomarker Analysis, Leucovorin Calcium, Melphalan, Mercaptopurine, Methotrexate, Pegfilgrastim, Pharmacological Study, Tacrolimus, Vincristine Sulfate
Biological · Procedure · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
101
States / cities
Palo Alto, California • Aurora, Colorado • Boulder, Colorado + 68 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 18, 2026, 3:55 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Individualizing Automated Closed Loop Glucose Control Through Pharmacokinetic Profiling in an Insulin-Only Bionic Pancreas

NCT03262116
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Humalog, Novolog, BC222 insulin lispro, Bionic Pancreas
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 9, 2022 · Synced Oct 18, 2026, 3:55 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)

NCT06390852
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Larotrectinib, Magnetic Resonance Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 18, 2026, 3:55 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Validation of an Obstacle Course Used in Patients With Muscle Tightness

NCT00776048
View directory record Official record
Conditions
Stroke, Traumatic Brain Injury, Multiple Sclerosis, Spasticity, Healthy Controls
Interventions
Not listed
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2010 · Synced Oct 18, 2026, 3:55 AM EDT
Completed Phase 1Phase 2 Interventional

A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study

NCT02875548
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Synovial Sarcoma, Epitheliod Sarcoma (ES), Mesothelioma, Advanced Solid Tumors, Renal Medullary Carcinoma, Non-Hodgkin Lymphoma (NHL)
Interventions
Tazemetostat
Drug
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
11
States / cities
Tucson, Arizona • Santa Fe, California • Port Saint Lucie, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 18, 2026, 3:55 AM EDT
Recruiting No phase listed Observational

A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

NCT07175285
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Current standard of care treatment options
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
26
States / cities
La Jolla, California • La Palma, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 18, 2026, 3:55 AM EDT
Active, not recruiting Phase 1 Interventional

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

NCT05020678
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma, Large-cell Lymphoma
Interventions
NKX019
Biological
Lead sponsor
Nkarta, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2038
U.S. locations
2
States / cities
Denver, Colorado • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 18, 2026, 3:55 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to Polyvalent HIV-1 Vaccine in HIV Uninfected Adults

NCT00061243
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 DNA vaccine with protein vaccine boost
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2010
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 26, 2008 · Synced Oct 18, 2026, 3:55 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Gulf War Illness (GWI) by Comparing GWI and Healthy Veterans

NCT00810225
View directory record Official record
Conditions
Gulf War Illness, Persian Gulf War Syndrome
Interventions
Not listed
Lead sponsor
Georgetown University
Other
Eligibility
Not listed
Enrollment
516 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 18, 2026, 3:55 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Endothelial Function, Arterial Stiffness and Components

NCT01439217
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Not listed
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
8 Years to 28 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Oct 18, 2026, 3:55 AM EDT
Terminated Phase 1 Interventional Results available

VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib

NCT03400176
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL)
Interventions
VAY736, ibrutinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
5
States / cities
La Jolla, California • Los Angeles, California • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 18, 2026, 3:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Brain Ketone Metabolism in Type 1 Diabetes

NCT02471040
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia
Interventions
Beta-hydroxybutyrate, Normal Saline
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 18, 2026, 3:55 AM EDT
Completed Phase 1 Interventional

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer

NCT00045006
View directory record Official record
Conditions
Cancer
Interventions
vorinostat
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 18, 2026, 3:55 AM EDT
Completed No phase listed Observational

PTNS on Urinary and Global Quality of Life in MS Patients

NCT04063852
View directory record Official record
Conditions
Multiple Sclerosis, Lower Urinary Tract Symptoms, Neurogenic Bladder, Overactive Bladder, Urinary Incontinence, Urinary Urge Incontinence
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
23 participants
Timeline
2019 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Oct 18, 2026, 3:55 AM EDT
Recruiting Not applicable Interventional

ECoG BMI for Motor and Speech Control

NCT03698149
View directory record Official record
Conditions
ALS, SCI - Spinal Cord Injury, Stroke, Multiple Sclerosis, Muscular Dystrophies
Interventions
PMT/Blackrock Combination Device
Device
Lead sponsor
Karunesh Ganguly
Other
Eligibility
21 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 18, 2026, 3:55 AM EDT
Completed Not applicable Interventional

The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic (CDC Group II) or Have Persistent Generalized Lymphadenopathy (CDC Group III)

NCT00002048
View directory record Official record
Conditions
Lymphatic Disease, HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
22
States / cities
La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 18, 2026, 3:55 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model

NCT00689078
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Prednisolone Acetate 1%, Prednisolone Acetate 0.12%, Loteprednol Etabonate 0.2%, Placebo
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 18, 2026, 3:55 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effects of Anthracycline-based Chemotherapy on Peripheral Vascular Function

NCT03062878
View directory record Official record
Conditions
Breast Cancer, Lymphoma, Chemotherapy Effect
Interventions
Arterial blood pressure, Vascular Ultrasound, Venous blood sample, Skin microcirculatory blood flow
Other
Lead sponsor
Carl Ade, M.S., Ph.D.
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Manhattan, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 18, 2026, 3:55 AM EDT
Completed No phase listed Observational

Collaborative Assessment of Pediatric Transverse Myelitis: Understand, Reveal, Educate or CAPTURE Study

NCT02144935
View directory record Official record
Conditions
Myelitis, Transverse, Flaccid Paraplegia, Complete, Acute, Flaccid Paraplegia, Incomplete, Acute
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Up to 17 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 18, 2026, 3:55 AM EDT
Active, not recruiting Early Phase 1 Interventional

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

NCT04541108
View directory record Official record
Conditions
Solid Tumor
Interventions
Rilvegostomig, Volrustomig, Sabestomig, Pembrolizumab, AZD9592, AZD9592 + Rilvegostomig, AZD9592 + Volrustomig, AZD9592 + Sabestomig, AZD9592 + Pembrolizumab
Biological · Combination Product
Lead sponsor
Presage Biosciences
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
9
States / cities
Shreveport, Louisiana • The Bronx, New York • Chapel Hill, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 18, 2026, 3:55 AM EDT
Enrolling by invitation No phase listed Observational

A Long Term Follow-Up Study for Subjects Who Have Received Q-Cells

NCT06163508
View directory record Official record
Conditions
Transverse Myelitis
Interventions
Q-Cells®
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Not listed
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 18, 2026, 3:55 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

PrEP Intervention in Prince George's County, Maryland

NCT06141408
View directory record Official record
Conditions
Hiv, Mental Health Issue, Support, Family
Interventions
MPowerment PrEP Promotion Intervention
Behavioral
Lead sponsor
George Mason University
Other
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 18, 2026, 3:55 AM EDT